Corporate | 20 November 2008 09:23
ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Miscellaneous
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Berlin, November 20, 2008. Eckert & Ziegler Strahlen- und Medizintechnik AG
(ISIN DE 0005659700) will in future be consolidating its activities in the
area of radiotherapy within one organization and on December 1, 2008 it
will be selling its tumor equipment division and other products for
treating cancer, with a combined sales volume of roughly 10 million EUR, to
the Belgian company International Brachytherapy S.A. (IBt). The
transaction, which will be worth approximately 5 million EUR, will be
financed by a long-term vendor loan.
Back in February, Eckert & Ziegler incorporated its Berlin-based implants
division into the listed Belgian company and in return for this it received
around 40% of the commercial shares in IBt as well as a long-term option to
acquire the majority of the shares. By selling off the rest of the therapy
activities remaining in Berlin and the commercial business in France to
IBt, all of the products for radiation therapists are now combined within
one organizational unit.
'Jobs remain unaffected by this measure,' explained Dr. Andreas Eckert,
founder and CEO of the company. 'Essentially the aim of this move is to
bring together the Group’s therapy activities under one management team
once again and to gain greater clout and presence in the market with the
enlarged organization. Together with IBt’s original implant business, the
transaction creates a focused specialist in radio-oncological products with
a sales volume of almost 30 million EUR. It will have interesting options
for expansion in different directions.'
Eckert & Ziegler AG, which in 2008 will achieve sales of approx. 70 million
EUR with around 420 employees, is one of the world’s largest providers of
isotope component technology for radiation therapy, nuclear medicine and
industrial applications.
Your contact:
Eckert & Ziegler AG
Karolin Riehle, Investor Relations & PR, Robert-Rössle-Str. 10, 13125
Berlin, Germany
Tel.: +49 (0) 30 / 941084-138, Fax-112, E-mail: karolin.riehle@ezag.de,
www.ezag.de
IBt s.a.
François Blondel, CEO
Laurence Goemaere, Investor Relations
Tel.: +32 (0)064.520811, E-mail: ir@ibt.be, www.ibt.be
20.11.2008 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Deutschland
Phone: +49 (0)30 941 084-0
Fax: +49 (0)30 941 084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------